Key statistics
As of last trade argenx SE (1AE:FRA) traded at 690.20, -14.20% below its 52-week high of 804.40, set on Nov 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 690.20 |
|---|---|
| High | 690.20 |
| Low | 690.20 |
| Bid | 694.80 |
| Offer | 715.80 |
| Previous close | 687.60 |
| Average volume | 194.33 |
|---|---|
| Shares outstanding | 61.88m |
| Free float | 61.88m |
| P/E (TTM) | 35.85 |
| Market cap | 43.06bn EUR |
| EPS (TTM) | 19.41 EUR |
Data delayed at least 15 minutes, as of Feb 10 2026 07:15 GMT.
More ▼
Announcements
- argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
- argenx Highlights 2026 Strategic Priorities
- argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
- argenx Announces Leadership Transition Marking Next Evolution of Growth
- argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
- argenx Announces Results of Extraordinary General Meeting of Shareholders
- argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
- argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
- argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
- argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
More ▼
